Don S. Dizon, MD, FACP, FASCO, is an oncologist who specializes in women's cancers. He is the director of women's cancers at Lifespan Cancer Institute and director of medical oncology at Rhode Island Hospital. He is an active member of the American Society of Clinical Oncology, SWOG cancer research network, and the National Consortium of Breast Cancers, of which he has served as both vice president and president. He is also the Editor of CA: A Cancer Journal for Clinicians, the highest impact and the flagship Journal of the American Cancer Society.

Brian Druker, MD, is the director of the Oregon Health & Science University (OHSU) Knight Cancer
Institute, associate dean for oncology of the OHSU School of Medicine and the JELD-WEN Chair of Leukemia Research. He performed preclinical studies that led to the development of imatinib (Gleevec) for chronic myeloid leukemia (CML) and then spearheaded the highly successful clinical trials of imatinib, which led to FDA approval of the drug in record time. This work changed the life expectancy of patients with CML, resulting in a paradigm shift in cancer treatment.

Dr. Melinda Hsu is a thoracic medical oncologist at University Hospitals Seidman Cancer Center and an Assistant Professor of Medicine at Case Western Reserve University, specializing in the care of patients with lung cancer, mesothelioma, and thymoma. Dr. Hsu's primary career objective is to investigate the experiences and optimize the care of long-term survivors of lung cancer patients. This interest has been deeply personal, as both of her parents were diagnosed with non-small cell lung cancer (NSCLC) 6 months apart in 2007.

Between 1999 and 2004, as Co-founder, CEO, Chairman, and President of the newly formed PanCAN-Pancreatic Cancer
Action Network, I created a unique
patient navigation and service programs “PALS”- Patient and Liaison Services and Clinical Trials database; along with pioneering programs for Survivor and Caregiver Networks; and Community Based Outreach and Education. For biomedical research, I established a public policy team and program that increased federal funding for pancreatic cancer by more than four hundred percent.

Stanley M. Marks, MD is chairman of UPMC Hillman Cancer Center, one of the largest integrated cancer networks in the country, and the only National Cancer Institute-designated comprehensive cancer center in western Pennsylvania. He is Director of clinical services and chief medical officer of UPMC Hillman Cancer Center and clinical professor of Medicine at the University of Pittsburgh School of Medicine. Dr. Marks has authored numerous publications and is the recipient of several additional awards including the National Research Service Award from the United States Public Health Service, the Art Rooney John McGrady Award, Heinz History Makers Award, Jerome Bettis Foundation Humanitarian Award, and Larry Richert Hometown Hero Award.

Debby brings a unique combination of strategic and executional strengths to more than 25 years of working with engineering and product teams bringing new technologies to market. Debby often works hands-on with company founders, helping to assemble world-class teams, architect software products, and establish a roadmap for success and scale. Additionally, given her broad set of operational skills and venture experience, Debby often works with venture capital firms providing great insight into markets and products as well as the technical operational capabilities of potential investment opportunities. Currently, she is working with Define Ventures as a Technical Advisor and Icon Ventures as an Operating Partner. Debby earned a Master's degree in computer science from Stanford University. She received her undergraduate degree in computer science and mathematics from the University of Michigan.

In 2001 Rodenbeck founded data visualization design studio Stamen, where he is Creative Director. The company’s high bar for elegant, data-driven design has brought many brilliant data artists, designers and technologists through its doors. The studio’s pioneering work in the field has inspired countless more. In 2017 Stamen was awarded the National Design Award for Interaction Design by the Cooper Hewitt Smithsonian Museum.

Dr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in hematology and oncology. Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs) and their use to help clinical quality efforts- including in the context of a clinical trial with an electronic PRO portal, through distress screening with the Stanford Medicine Cancer Center, and in improving access to such screening and care for patient with limited English proficiency. She is the recipient of both a clinical innovation award through Stanford and an American Society of Clinical Oncology (ASCO) Merit award.

Sasha K. Said’s mission is to support companies that have a large scale impact on human health. She spent her career helping companies build digital products that improve healthcare delivery. She currently consults as a fractional Chief Growth & Product Officer advising on: 1. Digital TPPs 2. Go-To-Market (GTM) strategies in pharma including: product ideation, product-market fit, competitive landscape, market sizing, market launch, sales, marketing, and business development (BD) 3. Evidence generation, white papers, and regulatory concerns 4. Capital raising. She was co-Founder/ Chairman of The Pharma Digital Health Roundtable convening 200+ life science leaders to discuss the adoption of digital solutions in biopharma and Founder of B7, over 100 women in VC and BD in Boston.
Said graduated from Brown University with a BA in Business Economics and East Asian History, rowed DI crew, and worked waiting tables and nannying.